Shikonin Induces Apoptosis and Inhibits Migration of Ovarian Carcinoma Cells by Inhibiting the Phosphorylation of Src and FAK

Overview

Journal Oncol Lett

Specialty Oncology

Date 2015 Jan 27

PMID 25621031

Citations 10

Authors

Zhenfeng Hao

Jing Qian

Jishi Yang

Affiliations

Soon will be listed here.

Abstract

The present study identified that shikonin, a naphthoquinone extracted from the roots of , inhibits the migration of ovarian cancer cells and induces their apoptosis by impairing the phosphorylation of two kinases, proto-oncogene tyrosine protein kinase Src (Src) and focal adhesion kinase (FAK). Ovarian carcinoma SKOV-3 cells were treated with various concentrations of shikonin and analyzed for the effects on cell migration, invasion and apoptosis via Transwell assays and flow cytometry. In addition, the effects of shikonin administration on the expression and phosphorylation of Src and FAK in the SKOV-3 cells were analyzed by western blotting. Shikonin appeared to induce apoptosis and decrease cell migration in the SKOV-3 ovarian cells. Furthermore, the present study provides evidence that shikonin may exert these effects on human ovarian carcinoma cells via the inhibition of the protein tyrosine kinases, Src and FAK. Thus, shikonin should be considered for additional investigation as a candidate agent for the prevention and treatment of human ovarian cancer.

Citing Articles

Shikonin reduces M2 macrophage population in ovarian cancer by repressing exosome production and the exosomal galectin 3-mediated β-catenin activation.

Wang M, Sun Y, Gu R, Tang Y, Han G, Zhao S J Ovarian Res. 2024; 17(1):101.

PMID: 38745186 PMC: 11092256. DOI: 10.1186/s13048-024-01430-3.

Remodeling tumor microenvironment with natural products to overcome drug resistance.

Zhang W, Li S, Li C, Li T, Huang Y Front Immunol. 2022; 13:1051998.

PMID: 36439106 PMC: 9685561. DOI: 10.3389/fimmu.2022.1051998.

Shikonin impedes type 2 ovarian cancer progression via FasL/caspase-8 and mir-874-3p/XIAP axis and prohibits the properties of stemness.

Chang Y, Lin Y, Huang C, Harnod T, Ding D Am J Cancer Res. 2022; 12(10):4584-4601.

PMID: 36381333 PMC: 9641410.

Shikonin Mediates Apoptosis through G Protein-Coupled Estrogen Receptor of Ovarian Cancer Cells.

Liu X, Yang Y, Tang X, Guo L, Tang X, Zhu T Evid Based Complement Alternat Med. 2022; 2022:6517732.

PMID: 36248433 PMC: 9556250. DOI: 10.1155/2022/6517732.

Shikonin induced Apoptosis Mediated by Endoplasmic Reticulum Stress in Colorectal Cancer Cells.

Qi H, Zhang X, Liu H, Han M, Tang X, Qu S J Cancer. 2022; 13(1):243-252.

PMID: 34976186 PMC: 8692675. DOI: 10.7150/jca.65297.

References

Wang W, Dai M, Zhu C, Zhang J, Lin L, Ding J . Synthesis and biological activity of novel shikonin analogues. Bioorg Med Chem Lett. 2008; 19(3):735-7. DOI: 10.1016/j.bmcl.2008.12.032. View

Westhoff M, Serrels B, Fincham V, Frame M, Carragher N . SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol Cell Biol. 2004; 24(18):8113-33. PMC: 515031. DOI: 10.1128/MCB.24.18.8113-8133.2004. View

Li W, Liu J, Jackson K, Shi R, Zhao Y . Sensitizing the therapeutic efficacy of taxol with shikonin in human breast cancer cells. PLoS One. 2014; 9(4):e94079. PMC: 3977981. DOI: 10.1371/journal.pone.0094079. View

Lam K . Development of inhibitors for protein tyrosine kinases. Oncogene. 2000; 19(49):5690-701. DOI: 10.1038/sj.onc.1203926. View

Lee H, Lee H, Magesh V, Nam D, Lee E, Ahn K . Shikonin, acetylshikonin, and isobutyroylshikonin inhibit VEGF-induced angiogenesis and suppress tumor growth in lewis lung carcinoma-bearing mice. Yakugaku Zasshi. 2008; 128(11):1681-8. DOI: 10.1248/yakushi.128.1681. View

Sankawa U, Otsuka H, Kataoka Y, Iitaka Y, Hoshi A, KURETANI K . Antitumor activity of shikonin, alkannin and their derivatives. II. X-ray analysis of cyclo-alkannin leucoacetate, tautomerism of alkannin and cyclo-alkannin and antitumor activity of alkannin derivatives. Chem Pharm Bull (Tokyo). 1981; 29(1):116-22. DOI: 10.1248/cpb.29.116. View

Hunter T . Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 1995; 80(2):225-36. DOI: 10.1016/0092-8674(95)90405-0. View

Wu Z, Wu L, Tashiro S, Onodera S, Ikejima T . Phosphorylated extracellular signal-regulated kinase up-regulated p53 expression in shikonin-induced HeLa cell apoptosis. Chin Med J (Engl). 2005; 118(8):671-7. View

Nakaya K, Miyasaka T . A shikonin derivative, beta-hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases. Anticancer Drugs. 2003; 14(9):683-93. DOI: 10.1097/00001813-200310000-00002. View

10.

Recher C, Ysebaert L, Beyne-Rauzy O, Mas V, Ruidavets J, Cariven P . Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res. 2004; 64(9):3191-7. DOI: 10.1158/0008-5472.can-03-3005. View

11.

Baron V, Calleja V, Ferrari P, Alengrin F, Van Obberghen E . p125Fak focal adhesion kinase is a substrate for the insulin and insulin-like growth factor-I tyrosine kinase receptors. J Biol Chem. 1998; 273(12):7162-8. DOI: 10.1074/jbc.273.12.7162. View

12.

Yang H, Zhou P, Huang H, Chen D, Ma N, Cui Q . Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer. 2009; 124(10):2450-9. PMC: 2707765. DOI: 10.1002/ijc.24195. View

13.

Roskoski Jr R . Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun. 2005; 331(1):1-14. DOI: 10.1016/j.bbrc.2005.03.012. View

14.

Schaller M, Borgman C, Cobb B, Vines R, Reynolds A, Parsons J . pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci U S A. 1992; 89(11):5192-6. PMC: 49256. DOI: 10.1073/pnas.89.11.5192. View

15.

Calalb M, Polte T, Hanks S . Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol. 1995; 15(2):954-63. PMC: 231984. DOI: 10.1128/MCB.15.2.954. View

16.

Wiener J, Windham T, Estrella V, Parikh N, Thall P, Deavers M . Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol. 2002; 88(1):73-9. DOI: 10.1006/gyno.2002.6851. View

17.

Wu Z, Wu L, Li L, Tashiro S, Onodera S, Ikejima T . p53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells. J Pharmacol Sci. 2004; 94(2):166-76. DOI: 10.1254/jphs.94.166. View

18.

Wheeler D, Iida M, Dunn E . The role of Src in solid tumors. Oncologist. 2009; 14(7):667-78. PMC: 3303596. DOI: 10.1634/theoncologist.2009-0009. View

19.

Hsu P, Huang Y, Tsai M, Wang Y, Lin J, Pan M . Induction of apoptosis by shikonin through coordinative modulation of the Bcl-2 family, p27, and p53, release of cytochrome c, and sequential activation of caspases in human colorectal carcinoma cells. J Agric Food Chem. 2004; 52(20):6330-7. DOI: 10.1021/jf0495993. View

20.

Yeh C, Kuo H, Li T, Lin J, Yu F, Lu H . Shikonin-induced apoptosis involves caspase-3 activity in a human bladder cancer cell line (T24). In Vivo. 2008; 21(6):1011-9. View